Integra LifeSciences Schedules Conference Call for Wednesday, November 7 to Discuss Third Quarter 2001 Financial Results and Provide Forward-Looking Earnings Guidance
Financial results for the third quarter of 2001 will be announced via a news release issued before the market opens on November 7.
The upcoming conference call, which will be hosted by Stuart Essig, President and Chief Executive Officer of Integra, is open to all listeners and will be followed by a question and answer session. Additional forward-looking information may be discussed in the question and answer session following the call.
Access to the live call is available by dialing 973/628-9554 or through a listen-only webcast via a link provided on the home page of Integra's website at http://www.integra-LS.com. A replay of the conference call will be accessible starting one hour following the live event.
Access to the replay is available through November 20, 2001 by dialing 973/341-3080 (pin code 2854902) or through the webcast accessible on our home page.
Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life.
The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world. The Company has approximately 585 permanent employees.
Statements made in the upcoming conference call may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results.
Forward-looking factors that may be discussed include, but are not limited to, expected financial results, new product development, governmental approvals, market potential, expected sales and potential therapeutic applications of new products, new sources of potential financing and additional acquisitions.
In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K/A for the year ended December 31, 2000 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation, Plainsboro
John Bostjancic, 609/936-2239
jbostjancic@integra-ls.com
URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright © 2001 Business Wire. All rights reserved.